Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117Phase 4Terminated
- Sponsor
- The University of Texas at Arlington
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic kidney disease (CKD) comparing Pioglitazone with Placebo (2 arms). Primary endpoint: Muscle Sympathetic Nerve Activity at 1 month. Started Apr 2018; status: terminated.
02
Drugs
pioglitazone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03471117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471117.